Special items: Ovarian Cancer and Us blog best viewed in Firefox

Monday, July 11, 2011

Targeting Src in Mucinous Ovarian Carcinoma (dasatinib/oxaliplatin)

"Targeting src kinase with combination of dasatinib and oxaliplatin may be an attractive approach in this disease."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.